SCHEMBL19247334

SCHEMBL19247334

c1ccc(-c2nc(-c3cccc(-n4c5ccccc5c5cc6c(cc54)oc4ccccc46)c3)c3c(n2)oc2ccccc23)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ATM Q13315 1/20 0.32
NPC1 O15118 2/20 0.32
HTT P42858 2/20 0.32
RAB9A P51151 2/20 0.32
HPGD P15428 2/20 0.32
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
POLB P06746 1/20 0.30
MAPK1 P28482 1/20 0.30
DUSP3 P51452 1/20 0.30
PTPN5 P54829 1/20 0.30
PTPN11 Q06124 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19246410 0.97 SMN1; SMN2 (0.35) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19247412 0.96 SMN1; SMN2 (0.35) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19246494 0.93 SMN1; SMN2 (0.35) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19247337 0.93 SMN1; SMN2 (0.39) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19247414 0.92 SMN1; SMN2 (0.39) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19247328 0.91 SMN1; SMN2 (0.35) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19246405 0.91 SMN1; SMN2 (0.35) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL19246411 0.91 SMN1; SMN2 (0.39) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL25146809 0.91 ATM (0.34) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9
SCHEMBL16905834 0.91 SMN1; SMN2 (0.38) SMN1; SMN2LMNAALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10873034-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-12-22 US disclosed
US-20170237015-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-08-17 US disclosed
US-20170237015-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170237015-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CCNA1, ARL1 SMN1; SMN2 2291/4885LMNA 1202/4885ALDH1A1 139/4885
US-10873034-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CCNA1, ARL1 SMN1; SMN2 2291/4885LMNA 1202/4885ALDH1A1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.